Hurley Capital LLC Sells 1,793 Shares of Pfizer Inc. (NYSE:PFE)

Hurley Capital LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 55.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,422 shares of the biopharmaceutical company’s stock after selling 1,793 shares during the quarter. Hurley Capital LLC’s holdings in Pfizer were worth $36,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. bought a new position in shares of Pfizer during the 1st quarter worth $28,000. Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the 4th quarter worth $30,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer during the 1st quarter worth $35,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent research reports. TD Cowen dropped their price target on Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research report on Tuesday, April 22nd. HSBC dropped their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Bank of America increased their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Finally, UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.55.

Pfizer Stock Performance

NYSE PFE opened at $24.33 on Tuesday. The company has a market cap of $138.33 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58. The stock’s 50 day simple moving average is $24.32 and its 200-day simple moving average is $24.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.82 earnings per share. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.07%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.